DILI (Drug-Induced Liver Injury) is liver damage or injury caused by the use of pharmaceutical drugs or medications. DILI can manifest in various forms, ranging from mild elevations in liver enzymes to severe liver failure. The severity of DILI can vary widely from person to person and depends on the individual's genetics and health, and the drug involved. Healthcare providers and researchers closely monitor the capability of drugs to cause DILI, and regulatory agencies have established guidelines for assessing and mitigating this risk during drug development. Understanding and managing DILI is crucial to ensuring the safety of pharmaceuticals and protecting patients from harm.

The Library of Most-DILI-Concern Drugs comprises a selection of pharmaceutical compounds known for their potential to induce liver injury in patients. These drugs have been extensively studied and documented for their hepatotoxic effects. Researchers and healthcare professionals can use this library for in-depth investigations into DILI mechanisms, risk factors, and possible mitigation strategies. It serves as a valuable resource for advancing our understanding of liver-related adverse drug reactions and improving drug safety profiles.

Related terms: H1 receptor, D2 receptor, carbonic anhydrase, acetylcholinesterase, COX-1, epidermal growth factor receptor, D3 receptor.